3TR Featured in IHI Webinar on In-Kind Contributions

On 11 March 2026, 3TR was featured in the Innovative Health Initiative (IHI) webinar Lifting the lid on in-kind contributions. During the session, Jörg Blankenstein from Sanofi presented the project as an example of how public-private collaboration can support ambitious health research.

Funded under IMI2, 3TR brings together 69 partners from academia, industry and patient organisations across 15 countries. The project studies seven immune-mediated diseases and aims to improve personalised treatment by identifying biomarkers and mechanisms linked to response and non-response to therapy. In doing so, 3TR helps researchers better understand disease trajectories and why some patients benefit from treatment while others do not.

In the webinar, Jörg Blankenstein showed how shared expertise, data and infrastructure help move a project of this scale forward and strengthen collaboration across disciplines. This is the added value of in-kind contributions in practice: combining resources from industry, academia and other partners to enable research that would not be possible otherwise. One example from 3TR is the federated analysis framework used in the IBD cluster. It allows partners to use a common analysis plan across clinical trials involving different companies, while keeping sensitive data with the respective partner and sharing only the results. The webinar highlighted how 3TR turns shared expertise and resources into practical collaboration, helping to accelerate progress towards more personalised treatment in immune-mediated diseases.

The webinar recording and presentation are available via the IHI website.